Eferalgan is generally used to provide supportive symptom management in situations involving mild to moderate discomfort and elevated body temperature. This therapeutic role is centered on the active ingredient's function in temporarily relieving pain and reducing fever.

---

Therapeutic Relief and Symptom Management

The medication is commonly used across conditions presenting with acute or disruptive episodes, such as short-term discomfort from minor injuries or post-procedural pain. It is relevant for managing symptoms related to systemic imbalance, including fever and generalized body aches associated with flu-like syndromes. Therapeutic support is relevant for a range of mild-to-moderate painful manifestations, including headaches, muscle pain, toothache, and menstrual cramps.

“Applied during phases of increased distress or discomfort, the medication provides support that helps ease the overall symptom burden.”

This assists with maintaining functional stability when symptoms interfere with routine activities, contributing to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases.

---

Quick Fact: Symptomatic Support for Pain and Fever

Area of Relief	Targeted Symptom Category
Analgesia	Mild to moderate pain
Antipyresis	Elevated body temperature (fever)
Context	Acute, episodic discomfort

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who Can and Cannot Use Eferalgan

Official regulatory documents strictly define the populations permitted, restricted, or prohibited from using Eferalgan (paracetamol).

Use of the medicine is contraindicated for individuals with known hypersensitivity to the active substance or any excipient in the formulation. It is also formally prohibited for patients diagnosed with severe hepatocellular impairment or severe active decompensated liver disease, due to documented risk factors.

Eligibility is often conditional based on existing comorbidity or physiological state. Patients with severe renal impairment (creatinine clearance le 30 mL/min), mild to moderate hepatic insufficiency (including Gilbert’s syndrome), or chronic alcoholism are instructed to use the medicine with caution, potentially requiring adjustment of the dosing interval. Caution is also advised for populations with glutathione depletion, such as those with chronic malnutrition or G6PD deficiency.

Regarding age, the standard 500 mg tablet formulation is typically not recommended for children under 10 years of age. However, infants and younger children are eligible for use via age- and weight-appropriate liquid or suppository forms. Use is permitted during both pregnancy and breastfeeding if clinically necessary, provided it is limited to the lowest effective dose for the shortest possible duration.

Interactions with other medicines and products

The official regulatory profile for Eferalgan (Paracetamol/Acetaminophen) outlines interactions across several pharmacological classes, primarily related to pharmacokinetic modification and potentiation effects. No specific medicinal product is listed as a formal contraindication in major government labels.

Key Interacting Substances and Effects

Substance Category	Documented Interaction Outcome
Oral Anticoagulants (e.g., Warfarin)	Enhances the anticoagulant effect and increases the risk of bleeding, particularly with high daily doses or prolonged use. This requires increased monitoring of the International Normalized Ratio (INR).
Enzyme Inducers (e.g., certain Anticonvulsants)	Increases the risk of toxicity due to enhanced formation of a toxic metabolite.

Pharmacokinetic and Timing Constraints

Substances affecting gastric movement and absorption rate are documented interactors. Agents such as Metoclopramide or Domperidone may increase the rate of Paracetamol absorption. Conversely, co-administration with Cholestyramine reduces absorption and requires a mandatory timing separation rule: Paracetamol must be administered at least one hour before or two to three hours after Cholestyramine to ensure efficacy.

Substance and Population-Specific Notes

Official labeling establishes specific restrictions based on substance consumption and population health. Severe liver damage is documented to occur if the medicine is used while an individual consumes three or more alcoholic drinks per day. The risk of interaction severity and toxicity is also officially noted as heightened for individuals with existing hepatic impairment or chronic malnutrition due to compromised clearance.

Eferalgan, containing paracetamol, exerts its primary pharmacodynamic effects predominantly within the Central Nervous System (CNS). Its mechanism involves multiple, interacting molecular pathways. The parent compound acts as an inhibitor of cyclooxygenase (COX) enzymes, particularly a centrally-expressed COX-2 isoform or variant, which reduces the synthesis of prostaglandin E2 ( PGE2) in the brain, notably in the hypothalamus, a key thermoregulatory center. This decreased PGE2 concentration modulates central thermoregulatory signaling.

Simultaneously, paracetamol is metabolized into N-arachidonoylphenolamine (AM404). This metabolite functions as an agonist by activating the transient receptor potential vanilloid 1 ( TRPV1) receptors and the cannabinoid type 1 ( CB1) receptors, primarily located in the brain and spinal cord. Activation of CB1 and TRPV1 channels modifies intracellular calcium dynamics, which in turn potentiates the activity of descending inhibitory serotonergic pathways. These system-level modulations collectively decrease afferent neuronal signaling within nociceptive pathways.

How Eferalgan is Used: Official Administration Guidelines

Eferalgan, which contains the active substance Paracetamol (Acetaminophen), is administered according to standardized dosing protocols. These guidelines define the proper routes of administration, the numerical limits for intake, and the required timing for its use.

---

Administration Routes and Forms

Official product labeling specifies three primary administration paths: the Oral route, the Rectal route (via suppositories), and the Intravenous (IV) route for infusion, which is reserved for use in clinical settings. Available dosage forms include standard tablets, effervescent tablets which must be dissolved completely in water, oral solutions requiring measurement with a calibrated device, and solutions for IV infusion.

---

Labeled Dosing and Frequency

Category	Official Instructions
Standard Adult Single Dose	Typically 500 mg to 1000 mg (1 g)
Maximum Daily Dose	Must not exceed 4000 mg (4 g) in a 24-hour period.
Dose Interval	A minimum interval of 4 hours is required between any two administrations.

Administration is generally described as being as-needed (PRN), repeatable every four to six hours up to the established daily maximum. The medicine is intended for short-term symptomatic management only, and continuous use beyond a few days (typically 3 to 5 days) requires clinical re-evaluation.

---

Population-Specific Use and Conditions

Dose adjustments are required for specific patient populations. For pediatric patients, dosing is calculated based on body weight, commonly at 15 mg per kilogram per dose. Adults with renal or hepatic impairment may require a reduction in the maximum daily dose and a prolonged interval between doses as per established guidelines. Intravenous administration requires the infusion to be delivered slowly over 15 minutes.

Research evidence / Overview of Studies for Eferalgan

---

Evidence for Use in Acute Pain Relief

Research examining the active substance in Eferalgan for acute physical discomfort, such as post-operative pain, dental pain, and episodic muscle aches, includes a large volume of Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies monitored changes in pain intensity and assessed patient-reported outcomes over short periods, typically within 24 hours of administration. The available data describes patterns observed in these populations, but follow-up durations were limited to the acute time frame. Consequently, research provides limited insight into long-term outcomes related to repeated use.

Evidence for Use in Fever Reduction (Antipyresis)

The substance was evaluated in studies exploring outcomes related to systemic or functional imbalance, such as fever. The evidence base relies on a large body of RCTs examining cohorts of adults and children. Research describes the patterns observed in the studies that measured changes in body temperature. A key limitation is that ethical considerations often prevent the use of a placebo in trials involving febrile children. Data for certain unique sub-groups, such as the critically ill, are still emerging.

Evidence for Use in Specific Chronic Conditions

The active substance was studied for conditions characterized by functional limitations such as osteoarthritis of the knee and hip. Research examined patient-reported outcomes and monitored functional scales over several weeks to months. Findings describe patterns observed in these specific conditions, but evidence quality varies across the full spectrum of chronic pain. Data show patterns related to findings of no observed change in outcome for conditions like acute low back pain.

---

Areas of Research Uncertainty and Gaps

The overall research landscape has identified several areas where certainty remains low. Evidence describes where the evidence base is limited, particularly for the effectiveness in many types of non-specific or complex chronic pain conditions beyond those well-studied. Findings were mixed, indicating that results apply only to the populations studied and cannot be extrapolated broadly across all pain types. Finally, while extensive data exist for acute use, the long-term effects are not fully established.

Key Studies & References

1. Paracetamol (Acetaminophen) Summary of Product Characteristics (SmPC) Assessment Report (Regulatory Evidence Base)

Common questions about Eferalgan (FAQ)

---

Q: Can I take it for migraines?

A: Eferalgan is officially approved for the treatment of (insert regulatory approved indication, e.g., mild to moderate pain or fever), according to official product information. Regulatory documents specify that its approved uses are limited to those indications listed on the label. Migraine is not specifically listed as an approved use in the official prescribing information.

Q: Can children 2 years old use it?

A: Official regulatory documents indicate that the approved dosing and administration instructions are provided for patients (state the minimum approved age, e.g., 6 years and older). The product information does not specify use for children 2 years old. Eligibility and appropriate dosing are determined based on the product's official age and weight guidelines. Patients are encouraged to review the product's official instructions for the minimum approved age.

Q: Does it make you sleepy?

A: Regulatory documents list possible side effects, which may include effects on the central nervous system such as (cite a relevant adverse reaction from the label, e.g., somnolence or dizziness). Not everyone experiences side effects, but official product information indicates that patients should be aware of the full range of reported adverse reactions.

Storage and Disposal of Eferalgan

Official regulatory documents define specific conditions for storing and discarding Eferalgan (paracetamol) to ensure stability and safety.

---

Required Storage Conditions

Requirement	Specifics
Temperature	Store certain formulations below mathbf25^circC or mathbf30^circC. Some effervescent tablets may require no special temperature conditions.
Protection	Store in the original package to protect from light and moisture. Keep containers tightly closed when applicable.
Child Safety	The medication must be kept out of the sight and reach of children.

---

Disposal Instructions

Any unused or expired Eferalgan product must be disposed of in accordance with local requirements. The medication must not be thrown away via wastewater or household waste to prevent environmental contamination. This mandates utilizing official pharmaceutical take-back programs or authorized collection sites.